In this episode of Derms and Conditions, host Dr James Q. Del Rosso returns from the 2025

Winter Clinical Dermatology Conference – Miami® with a deep dive into some of the standout

posters presented at the meeting.

Dr Del Rosso begins the review with new insights on topical clascoterone 1% cream and its

impact on the skin barrier, tolerability, and sebum reduction. He explores recent studies

showing that clascoterone does not compromise the permeability barrier or increase

transepidermal water loss—key considerations for its use alongside other acne treatments like

benzoyl peroxide and topical retinoids.

The analysis shifts to a comparative study on a triple combination acne therapy featuring

clindamycin 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1%, which demonstrated superior

efficacy over dual-combination formulations. Dr Del Rosso breaks down early activity data,

inflammatory and non-inflammatory lesion reductions, and how polymeric emulsion

technology enhances both efficacy and tolerability.

He also highlights new data on topical ruflomilast for atopic dermatitis in younger patients

(ages 2-5) and explores the recent FDA approval of tapinarof 1% cream for atopic dermatitis

down to age two. Posters on itch and sleep improvements in pediatric patients, as well as

efficacy in skin of color, provide valuable clinical insights.

Tune in for this rapid-fire breakdown of key posters, packed with data-driven takeaways to

enhance your dermatology practice.